Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

NOVEL PYRAZOLE-BASED HMG CoA REDUCTASE INHIBITORS

a technology of coa reductase inhibitor and pyrazole, which is applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of statin interference with and/or inhibiting hmg-coa, early and rate-limiting step in conversion of hmg-coa to mevalonate,

Inactive Publication Date: 2009-07-02
WARNER LAMBERT CO LLC
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The conversion of HMG-CoA to mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway.
To varying degrees, statins interfere with and / or inhibit HMG-CoA reductase from catalyzing the conversion of HMG-CoA to mevalonate.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NOVEL PYRAZOLE-BASED HMG CoA REDUCTASE INHIBITORS
  • NOVEL PYRAZOLE-BASED HMG CoA REDUCTASE INHIBITORS
  • NOVEL PYRAZOLE-BASED HMG CoA REDUCTASE INHIBITORS

Examples

Experimental program
Comparison scheme
Effect test

example 1

(3R,5R)-7-[5-benzylcarbamoyl-2-(4-fluoro-phenyl)-4-isopropyl-2H-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt

[0316]

(a) Step A. Preparation of [(4-Fluoro-phenyl)-hydrazono]-chloroacetic acid methyl ester

[0317]

(Reference: Tetrahedron Asymmetry 1999, 4447-4454): To a solution of 4-fluoroaniline (10.0 g, 90.0 mmol; commercially available from Sigma Aldrich) in MeOH (80 mL) was added 6 N HCl (80 mL) and the solution was cooled to 0° C. NaNO2 (12.4 g, 180 mmol) was then slowly added as a solid. The reaction was stirred for 15 min at 0° C. after which time NaOAc was added as a solid to adjust the reaction to pH 5. Subsequently, a solution of methyl 2-chloroacetoacetate (10.96 mL, 90.0 mmol; commercially available from Sigma Aldrich) in MeOH (40 mL) was slowly added at 0° C. The reaction was then allowed to warm to 25° C. and stirred for 12 hr after which time the MeOH was removed under reduced pressure and ether (300 mL) was added. The organic layer was separated and washed with s...

example 2

(3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(2-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt

[0343]

[0344]The title compound was prepared in a manner analogous to the method of Example 1. MS (APCI+): m / z 510.2 (M−H); H-NMR (DMSO-d6) δ 7.53-7.50 (m, 2H), 7.30 (t, 2H), 7.20-7.17 (m, 1H), 7.08-7.05 (m, 3H), 4.33 (s, 3H), 3.61-3.59 (m, 1H), 3.45-3.44 (m, 1H), 3.25 (bs, 1H), 2.73-2.67 (m, 1H), 2.58-2.51 (m, 1H), 2.24 (s, 3H), 1.94-1.89 (m, 1H), 1.75-1.69 (m, 1H), 1.37-1.10 (m, 10H).

example 3

(3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(3-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt

[0345]

[0346]The title compound was prepared in a manner analogous to the method of Example 1: MS (APCI+): m / z 512.2 (M+H); H-NMR (DMSO-d6) δ 7.53-7.49 (m, 2H), 7.30 (t, 2H), 7.14-6.95 (m, 4H), 4.30 (s, 2H), 3.62-3.55 (m, 1H), 3.46-3.42 (m, 1H), 3.26-3.19 (m, 1H), 2.69-2.61 (m, 1H), 2.58-2.51 (m, 1H), 2.21 (s, 3H), 1.91-1.88 (m, 1H), 1.72-1.66 (m, 1H), 1.34-1.10 (m, 10H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.

Description

RELATED APPLICATIONS[0001]This application is a continuing application of U.S. application Ser. No. 11 / 283,264, filed on Nov. 18, 2005, which claims benefit of priority under 35 U.S.C 119(e) to U.S. Provisional Application No. 60 / 630,481 filed on Nov. 23, 2004, the contents of which are hereby incorporated by reference.BACKGROUND OF THE INVENTION[0002]High levels of blood cholesterol and blood lipids are conditions involved in the onset of atherosclerosis. The conversion of HMG-CoA to mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway. This step is catalyzed by the enzyme HMG-CoA reductase. It is known that inhibitors of HMG-CoA reductase are effective in lowering the blood plasma level of low density lipoprotein cholesterol (LDL-C), in man. (cf. M. S. Brown and J. L. Goldstein, New England Journal of Medicine, 305, No. 9, 515-517 (1981)). It has been established that lowering LDL-C levels affords protection from coronary heart disease (cf. Journal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5377C07D231/14C07D413/06C07D405/06A61K31/415
CPCC07D231/12C07D231/14C07D405/06C07D401/12C07D401/06A61P13/08A61P19/10A61P25/28A61P35/00A61P3/06A61P43/00A61P9/00A61P9/10A61P3/10A61K31/415
Inventor CHOI, CHULHOBOWLES, DANIEL MERRITTHUTCHINGS, RICHARD H.PARK, WILLIAM K.C.PFEFFERKORN, JEFFREY A.
Owner WARNER LAMBERT CO LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com